Click the button below to start exploring our website and learn more about our awesome company
Start exploring

NX and MHL participated in the physique preparation and revised the paper

NX and MHL participated in the physique preparation and revised the paper. to CD14-expressing monocytes (see Additional file 1: Physique S1b for confirmation of CD14 expression). Significantly higher IL-6 levels in the monocyte culture medium were observed after 24?h of incubation with the supernatant of the effector/target coculture than immediately after beginning the incubation, which was used as the baseline level for comparison (Fig.?1c). In contrast, there were no differences in IL-6 or other cytokine levels in the monocyte culture medium after the addition of supernatants from untransduced T cells cocultured with Raji cells when comparing the same study time points. To pinpoint which cytokines are the main triggering factors that 25-Hydroxy VD2-D6 enhance IL-6 release from monocytes, we incubated primary monocytes with recombinant IL-1, IL-2, IL-6, or IFN- for 48?h, and then the released IL-6 level was measured by flow cytometry. To determine whether the enhancement in the IL-6 level is derived from activated monocytes, the amount of exogenous IL-6 was subtracted from the level measured in the monocyte culture medium. Incubation with IL-6 triggered a remarkable enhancement in the release of IL-6 from monocytes, with almost 100 times more IL-6 release in the IL-6-treated group than in the negative control group that was not incubated with any cytokines (Fig.?1d). The increases in IL-6 levels were also observed to be 25 and 3 times higher for the monocytes incubated with IL-1 or IFN- than for the negative control monocytes, respectively. In contrast, IL-2 did not trigger IL-6 release. These data demonstrated that IL-6 was the most potent cytokine in triggering monocyte IL-6 release under our experimental conditions. IL-6 knockdown does not impair basic properties of the ssCART-19 T cells To investigate whether the introduction of an IL-6-specific shRNA to regular CART-19 cells changes basic cell properties, we first designed 8 different IL-6-targeting shRNA sequences and cloned them into lentiviral vectors containing the CAR construct. IL-6 shRNA-2, which had the best IL-6 gene knockdown efficiency (70%) (Fig.?2a) and the highest IFN-/IL-6 mRNA ratio (73%) (Fig.?2b), was selected for this study. We then constructed CAR vectors containing a 4-1BB costimulatory domain, CD3 zeta domain and CD19-targeted single-chain variable fragment (FMC63) with or Klf2 without IL-6 shRNA-2 (Fig.?2c). T cells transduced with CD19-CAR were called regular CART-19 cells, and those transduced with CD19-CAR and IL-6 shRNA-2 were designated ssCART-19 cells for subsequent experiments. Open in a separate window Fig.?2 IL-6 knockdown in ssCART-19 T cells does not impair basic properties of CAR T cells. a IL-6 mRNA levels and b IFN-/IL-6 mRNA ratios in CART-19 cells expressing 8 different IL-6-specific shRNAs. c Schematic of the CD19 CAR vector containing an anti-human CD19 scFv linked to 4-1BB costimulatory domains and CD3- signaling domain with (ssCART-19) or without (regular CART-19) an IL-6-specific shRNA modification. d Transduction efficiency and the CD4/CD8 ratio of 25-Hydroxy VD2-D6 ssCART-19 and CART-19 cells. e Cell proliferation of ssCART-19 cells and regular CART-19 cells after re-stimulation with Raji cells, as analyzed by flow cytometry. f CD107a expression in ssCART-19 cells and regular CART-19 cells after induction with Raji cells. g Cytotoxicity of ssCART-19 and CART-19 cells to K562 cells, Raji cells and autologous primary acute B lymphocytic leukemia cells at different effector: target ratios. Differences among groups were assessed for significance by using one-way ANOVA. Data are shown as the mean??SD (n?=?3). NS, no significant difference, *p??0.05, **p??0.01; ***p??0.001, ****p??0.0001 Then, the basic properties of ssCART-19 cells, including transduction efficiency, the CD4/CD8 ratio after transduction, proliferation, and cytotoxicity to the corresponding cancer cells were characterized and compared with the same features of regular CART-19 cells. The ssCART-19 cells showed cell properties similar to those of the regular CAR T-19 cells in terms of the level of transduction efficiency (45.7% vs 38.1%), the ratio of CD4/CD8 (Fig.?2d), proliferation (Fig.?2e) and cytotoxicity 25-Hydroxy VD2-D6 as measured by a CD107a (Fig.?2f) degranulation assay or cytotoxicity assay when cocultured with either Raji cells or patient-derived primary B-ALL cells (Fig.?2g). Thus, the results.